Clinical Trials

Istari Oncology is committed to the successful clinical development and registration of PVSRIPO and other technologies for the treatment of cancer.

PVSRIPO

PVSRIPO has been granted Breakthrough Therapy and Orphan Drug Designation by FDA in recurrent glioblastoma (rGBM).

PVSRIPO has been granted Orphan Drug Designation by FDA in advanced melanoma.

Current Clinical Trials

• Recruiting
  Recurrent Glioblastoma:
  
  Click here for the LUMINOS-101 infographicLUMINOS-101: PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma

• Recruiting
  Melanoma:
  
  Click here for the LUMINOS-102 infographicLUMINOS-102: PVSRIPO With or Without Immune Checkpoint Blockade in Patients with Advanced anti-PD-1 Refractory Melanoma

• Recruiting
  Advanced solid tumors:
  
  Click here for the LUMINOS-103 infographicLUMINOS-103: A Basket Trial Evaluating PVSRIPO and PVSRIPO With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors

ATC

We are currently evaluating D2C7 in a dose escalation Phase 1 study, which began in 2014. The study is scheduled to end in 2020. A combination trial, D2C7 plus atezolizumab, is currently enrolling.

Current Clinical Trials

• Recruiting
  Recurrent Glioblastoma:
  D2C7 for Adult Patients With Recurrent Malignant Glioma
  D2C7 With Atezolizumab for Recurrent Gliomas